Clinical Observation of Treatment for Advanced Colorectal Cancer with S-1 Plus Oxaliplatin_West China Medical Journal

Authors：

LONG Jieran , HE Jianping , ZHU Wenyan , LIU Jiyan ,  YI Cheng , LUO Deyun , BI Feng , XU Feng

Department of Abdominal Oncology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China;

Corresponding?author：

YI Cheng, Email: btl-060@163.com

Keywords：

替吉奧; 奧沙利鉑; 晚期結直腸癌

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

目的　觀察替吉奧膠囊聯合奧沙利鉑治療晚期結直腸癌的近期療效和毒性反應。方法　2011年5月－12月，將30例晚期結直腸癌患者根據體表面積來確定初始劑量，體表面積＜1.25 m2者，替吉奧膠囊40 mg/次，2次/d；體表面積1.25～1.50 m2者，替吉奧膠囊50 mg/次，2次/d；體表面積＞1.50 m2者，替吉奧膠囊60 mg/次，2次/d。早飯后和晚飯后分別口服1次，第1～4天服用奧沙利鉑注射液 130 mg/ m2，靜脈滴注，第1、21天重復，此為1個月周期。連用2周期后，按美國國立癌癥研究所擬定的藥物不良反應的分級評價標準3.0版本評價不良反應，按實體瘤治療療效評價標準評價療效。結果　30例患者中，完全緩解1例（3.3%），部分緩解7例（23.3%），穩定12例（40%），進展10例（33.3%），疾病控制率為66.6%。不良反應主要是血液學毒性、胃腸道反應、皮膚色素沉著及外周神經毒性；1例Ⅳ度骨髓抑制，3例3度貧血，2例3度腹瀉，2例3度皮膚色素沉著，2例3度惡心、嘔吐，其余且均在Ⅰ～Ⅱ度骨髓抑制。結論　替吉奧膠囊聯合奧沙利鉑方案治療晚期結直腸癌可獲得較高的疾病控制率，不良反應可控。

Citation： LONG Jieran,HE Jianping,ZHU Wenyan,LIU Jiyan,YI Cheng,LUO Deyun,BI Feng,XU Feng. Clinical Observation of Treatment for Advanced Colorectal Cancer with S-1 Plus Oxaliplatin. West China Medical Journal, 2012, 27(5): 693-696. doi: Copy

1.	de Gramont A, Figer A, Seymour M, et al. Leucovorin and ?uorouracil with or without oxaliplatin as ?rst-line treatment in advanced colorectal cancer[J]. J Clin Oncol, 2000, 18(16): 2938-2947.
2.	Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated ?uorouracil-leucovorin as ?rst-line treatment of metastatic colorectal cancer[J]. J Clin Oncol, 2000, 18(1): 136-147.
3.	Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with ?uorouracil compared with ?uorouracil alone as ?rst-line treatment for metastatic colorectal cancer: a multicentre randomised trial[J]. Lancet, 2000, 355(9209): 1041-1047.
4.	Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer[J]. N Engl J Med, 2005, 352: 476-487.
5.	Cassidy J, Clarke S, Díaz-Rubio E, et al. Randomized phase Ⅲ study of capecitabine plus oxaliplatin compared with ?uorouracil/folinic acid plus oxaliplatin as ?rst-line therapy for metastatic colorectal cancer[J]. J Clin Oncol， 2008，26(12): 2006-2012.
6.	Diaz-Rubio E, Tabernero J, Gomez-Espana A， et al. Phase Ⅲ study of capecitabine plus oxaliplatin compared with continuous-infusion ?uorouracil plus oxaliplatin as ?rst-line therapy in metastatic colorectal cancer: ?nal report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial[J]. J Clin Oncol, 2007, 25(27): 4224-4230.
7.	Ohtsu A, Baba H, Sakata Y, et al. PhaseⅡ study of S-1, a novel oral ?uoropyrimidine derivative, in patients with metastatic colorectal carcinoma.[J]. Br J Cancer， 2000，83(2): 141-145.
8.	Shirao K, Ohtsu A, Takada H, et al. PhaseⅡ study of oral S-1 for treatment of metastatic colorectal carcinoma[J]. Cancer, 2004, 100(11): 2355-2361.
9.	Malik ST, Talbot D, Clarke PI, et al. PhaseⅡ trial of UFT in advanced colorectal and gastric cancer[J]. Br J Cancer, 1990, 62(6): 1023-1025.
10.	Mathé G, Kidani Y, Segiguchi M, et al. Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum[J]. Biomed Pharmacother, 1989, 43(4): 237-250.
11.	王艷榮，張芳.運用奧沙利鉑聯合化療治療大腸癌的觀察及護理[J].現代護理，2001，7(10): 39.
12.	羅麗瑩，呂韶敏，劉文超.奧沙利鉑聯合氟尿嘧啶四氫葉酸治療胃腸道惡性腫瘤43例[J].第四軍醫大學學報，2002，23(5): 475.
13.	萬以葉.草酸鉑聯合氟尿嘧啶、甲酰四氫葉酸治療晚期大腸癌的療效觀察[J].中國癌癥雜志，2001，11(6):566.
14.	Fischel JL, Formento P, Ciccolini J, et al. Impact of the oxaliplatin-5 fluorouracil-folinic acid combination on respective intracellular determinants of drug activity[J]. Br J Cancer, 2002, 86(7): 1162-1168.
15.	Boisdron-Celle M，Craipeau C，Brienza S，et al，Influence of oxaliplatin on 5-fluorouracil plasma clearance and clinical consequences[J]. Cancer Chemother Pharmacol，2002，49(3): 235-243.
16.	Li J, Yin J, Zhu X, et al. PhaseⅠ dose-escalating study of S-1 in combination with oxaliplatin for patients with advanced and/or metastatic colorectal cancer[J]. Anticancer Drugs, 2008, 19(7): 745-748.
17.	Kim HS, Park MJ, Uhm JE, et al. A phaseⅠ trial of S-1 with oxaliplatin in patients with relapsed and metastatic colorectal cancer[J]. Int J Colorectal Dis, 2009, 24(11): 1311-1316.
18.	Hong YS, Lee JL, Park JH, et al. PhaseⅠ study of preoperative chemoradiation with S-1 and oxaliplatin in patients with locally advanced resectable rectal cancer[J]. Int J Radiat Oncol Biol Phys, 2011, 79(3): 684-689.
19.	Zang DY, Lee BH, Park HC, et al. PhaseⅡ study with oxaliplatin and S-1 for patients with metastatic colorectal cancer[J]. Ann Oncol, 2009, 20(5): 892-896.
20.	Doi Y, Okada T, Matsumoto H, et al. Combination therapy of metronomic S-1 dosing with oxaliplatin-containing polyethylene glycol-coated liposome improves antitumor activity in a murine colorectal tumor model[J]. Cancer Sci, 2010, 101(11): 2470-2475.
21.	Hong J, Han SW, Ham HS, et al. PhaseⅡ study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis[J]. Cancer Chemother Pharmacol, 2011, 67(6): 1323-1331.

1. 　de Gramont A, Figer A, Seymour M, et al. Leucovorin and ?uorouracil with or without oxaliplatin as ?rst-line treatment in advanced colorectal cancer[J]. J Clin Oncol, 2000, 18(16): 2938-2947.
2. 　Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated ?uorouracil-leucovorin as ?rst-line treatment of metastatic colorectal cancer[J]. J Clin Oncol, 2000, 18(1): 136-147.
3. 　Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with ?uorouracil compared with ?uorouracil alone as ?rst-line treatment for metastatic colorectal cancer: a multicentre randomised trial[J]. Lancet, 2000, 355(9209): 1041-1047.
4. 　Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer[J]. N Engl J Med, 2005, 352: 476-487.
5. 　Cassidy J, Clarke S, Díaz-Rubio E, et al. Randomized phase Ⅲ study of capecitabine plus oxaliplatin compared with ?uorouracil/folinic acid plus oxaliplatin as ?rst-line therapy for metastatic colorectal cancer[J]. J Clin Oncol， 2008，26(12): 2006-2012.
6. 　Diaz-Rubio E, Tabernero J, Gomez-Espana A， et al. Phase Ⅲ study of capecitabine plus oxaliplatin compared with continuous-infusion ?uorouracil plus oxaliplatin as ?rst-line therapy in metastatic colorectal cancer: ?nal report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial[J]. J Clin Oncol, 2007, 25(27): 4224-4230.
7. 　Ohtsu A, Baba H, Sakata Y, et al. PhaseⅡ study of S-1, a novel oral ?uoropyrimidine derivative, in patients with metastatic colorectal carcinoma.[J]. Br J Cancer， 2000，83(2): 141-145.
8. 　Shirao K, Ohtsu A, Takada H, et al. PhaseⅡ study of oral S-1 for treatment of metastatic colorectal carcinoma[J]. Cancer, 2004, 100(11): 2355-2361.
9. 　Malik ST, Talbot D, Clarke PI, et al. PhaseⅡ trial of UFT in advanced colorectal and gastric cancer[J]. Br J Cancer, 1990, 62(6): 1023-1025.
10. 　Mathé G, Kidani Y, Segiguchi M, et al. Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum[J]. Biomed Pharmacother, 1989, 43(4): 237-250.
11. 　王艷榮，張芳.運用奧沙利鉑聯合化療治療大腸癌的觀察及護理[J].現代護理，2001，7(10): 39.
12. 　羅麗瑩，呂韶敏，劉文超.奧沙利鉑聯合氟尿嘧啶四氫葉酸治療胃腸道惡性腫瘤43例[J].第四軍醫大學學報，2002，23(5): 475.
13. 　萬以葉.草酸鉑聯合氟尿嘧啶、甲酰四氫葉酸治療晚期大腸癌的療效觀察[J].中國癌癥雜志，2001，11(6):566.
14. 　Fischel JL, Formento P, Ciccolini J, et al. Impact of the oxaliplatin-5 fluorouracil-folinic acid combination on respective intracellular determinants of drug activity[J]. Br J Cancer, 2002, 86(7): 1162-1168.
15. 　Boisdron-Celle M，Craipeau C，Brienza S，et al，Influence of oxaliplatin on 5-fluorouracil plasma clearance and clinical consequences[J]. Cancer Chemother Pharmacol，2002，49(3): 235-243.
16. 　Li J, Yin J, Zhu X, et al. PhaseⅠ dose-escalating study of S-1 in combination with oxaliplatin for patients with advanced and/or metastatic colorectal cancer[J]. Anticancer Drugs, 2008, 19(7): 745-748.
17. 　Kim HS, Park MJ, Uhm JE, et al. A phaseⅠ trial of S-1 with oxaliplatin in patients with relapsed and metastatic colorectal cancer[J]. Int J Colorectal Dis, 2009, 24(11): 1311-1316.
18. 　Hong YS, Lee JL, Park JH, et al. PhaseⅠ study of preoperative chemoradiation with S-1 and oxaliplatin in patients with locally advanced resectable rectal cancer[J]. Int J Radiat Oncol Biol Phys, 2011, 79(3): 684-689.
19. 　Zang DY, Lee BH, Park HC, et al. PhaseⅡ study with oxaliplatin and S-1 for patients with metastatic colorectal cancer[J]. Ann Oncol, 2009, 20(5): 892-896.
20. 　Doi Y, Okada T, Matsumoto H, et al. Combination therapy of metronomic S-1 dosing with oxaliplatin-containing polyethylene glycol-coated liposome improves antitumor activity in a murine colorectal tumor model[J]. Cancer Sci, 2010, 101(11): 2470-2475.
21. 　Hong J, Han SW, Ham HS, et al. PhaseⅡ study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis[J]. Cancer Chemother Pharmacol, 2011, 67(6): 1323-1331.

West China Medical Journal

Clinical Observation of Treatment for Advanced Colorectal Cancer with S-1 Plus Oxaliplatin

Abstract Full text Figures/Tables Video References Cited by

Format

Content